Gut Associated Metabolites Enhance PD-L1 Blockade Efficacy in Prostate Cancer.

Two gut-associated metabolites, 16(R)-HETE and 6-Keto-PGE1, were identified as positively correlated with plasma exosomal PD-L1 levels in prostate cancer patients.

• The study recruited 70 prostate cancer patients divided into five subgroups.
• Integrated multi-omics analysis was performed to identify these correlations.
• 16(R)-Hydroxyeicosatetraenoic acid (16(R)-HETE) and 6-Keto-Prostaglandin E1 (6-Keto-PGE1) were the two identified metabolites.
• The correlation was specifically with plasma exosomal PD-L1 levels.

Both 16(R)-HETE and 6-Keto-PGE1 enhanced PD-L1 expression at the mRNA, protein, and exosome levels in prostate cancer cell lines.

• Enhancement of PD-L1 expression was observed in both human and mouse prostate cancer cell lines.
• PD-L1 upregulation was confirmed at multiple molecular levels: mRNA, protein, and exosomal PD-L1.
• These in vitro findings were validated in vivo using subcutaneous mouse models.

Both metabolites significantly promoted anti-PD-L1 efficacy against prostate cancer in situ in a TRAMP mouse model.

• Validation was performed using the transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
• Both 16(R)-HETE and 6-Keto-PGE1 were tested for their ability to enhance immune checkpoint inhibitor (ICI) efficacy.
• The in situ TRAMP model was used to assess clinically relevant anti-tumor immune responses.
• The findings suggest these metabolites can boost immune checkpoint inhibitor treatment outcomes in prostate cancer.

The gut microbiome modulates prostate cancer immunotherapy response through exosome-mediated regulation of PD-L1.

• The study explored how gut metabolites regulate PD-L1 blockade via exosomes.
• Plasma exosomal PD-L1 was identified as a key intermediate linking gut metabolites to immunotherapy response.
• The mechanism involves a 'gut-tumor metabolic axis' connecting gut microbiome-associated metabolites to tumor immune checkpoint expression.
• Multi-omics analysis was used to characterize this axis in 70 prostate cancer patients organized into five subgroups.

Targeting the gut-tumor metabolic axis is proposed as a strategy to improve immune checkpoint inhibitor efficacy in prostate cancer.

• The authors identified the 'gut-tumor metabolic axis' as a promising therapeutic target.
• This strategy aims to enhance the efficacy of immune checkpoint inhibitors (ICIs) in tumors.
• The approach was validated through both in vitro cell line experiments and in vivo transgenic mouse models.
• The study suggests broader applicability of this axis beyond prostate cancer to other tumors.